Decoding immune heterogeneity in bladder cancer : From cellular cartography to ex vivo models and antibody-based targeting
Bladder cancer is the ninth most common type of cancer globally, and the projected number of deaths is estimated to almost double by the year 2040. Immunotherapy with checkpoint inhibitors has revolutionized treatment of bladder cancer and can achieve durable responses; however, only a minority of patients respond. By identifying additional targets and treatment combinations, more patients could b
